SG Americas Securities LLC Purchases New Shares in Arbutus Biopharma Co. (NASDAQ:ABUS)

SG Americas Securities LLC purchased a new stake in Arbutus Biopharma Co. (NASDAQ:ABUS) in the 3rd quarter, HoldingsChannel.com reports. The fund purchased 52,869 shares of the biopharmaceutical company’s stock, valued at approximately $204,000.

Several other institutional investors also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC increased its stake in Arbutus Biopharma by 102.2% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 208,152 shares of the biopharmaceutical company’s stock valued at $643,000 after buying an additional 105,228 shares during the period. The Manufacturers Life Insurance Company increased its stake in Arbutus Biopharma by 7.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,323 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 4,191 shares during the period. Bank of Montreal Can increased its stake in Arbutus Biopharma by 6.1% in the 2nd quarter. Bank of Montreal Can now owns 354,813 shares of the biopharmaceutical company’s stock valued at $1,100,000 after buying an additional 20,548 shares during the period. Rubric Capital Management LP acquired a new position in Arbutus Biopharma in the 2nd quarter valued at $5,195,000. Finally, XTX Topco Ltd acquired a new position in Arbutus Biopharma in the 2nd quarter valued at $53,000. 43.79% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Jefferies Financial Group boosted their price objective on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 10th. Finally, JMP Securities upped their price target on shares of Arbutus Biopharma from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Arbutus Biopharma currently has an average rating of “Moderate Buy” and an average price target of $5.25.

Arbutus Biopharma Stock Down 1.0 %

NASDAQ:ABUS opened at $4.03 on Wednesday. Arbutus Biopharma Co. has a fifty-two week low of $1.69 and a fifty-two week high of $4.72. The stock has a market cap of $760.53 million, a PE ratio of -9.16 and a beta of 1.91. The firm’s fifty day simple moving average is $4.00 and its 200-day simple moving average is $3.50.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Arbutus Biopharma had a negative return on equity of 66.68% and a negative net margin of 766.20%. The company had revenue of $1.73 million for the quarter, compared to analyst estimates of $1.54 million. During the same period last year, the company earned ($0.10) earnings per share. Equities analysts anticipate that Arbutus Biopharma Co. will post -0.38 earnings per share for the current year.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.